Phase III Trial Achieves “Exceptional” Results
A new clinical trial showed that personalized treatment durations based on blood tests greatly enhance survival and remission in CLL, marking a major advancement in leukemia therapy.Personalized therapy enhances survival rates for patients with CLL leukemia.A phase III trial conducted by the University of Leeds discovered that personalized treatment for the most prevalent type of adult leukemia extends patient survival and maintains remission.This significant research was recently published in the New England Journal of…